Issue 2/2020
Content (15 Articles)
Drug Exposure to Establish Pharmacokinetic–Response Relationships in Oncology
Belén P. Solans, María Jesús Garrido, Iñaki F. Trocóniz
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review
Joshua P. Havens, Anthony T. Podany, Kimberly K. Scarsi, Courtney V. Fletcher
Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature
Stan J. F. Hartman, Roger J. Brüggemann, Lynn Orriëns, Nada Dia, Michiel F. Schreuder, Saskia N. de Wildt
A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Julie M. Janssen, T. P. C. Dorlo, D. Niewerth, A. J. Wilhelm, C. M. Zwaan, J. H. Beijnen, A. Attarbaschi, A. Baruchel, F. Fagioli, T. Klingebiel, B. De Moerloose, G. Palumbo, A. von Stackelberg, G. J. L. Kaspers, A. D. R. Huitema
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
Ken Ogasawara, Kathryn Newhall, Stephen E. Maxwell, Justine Dell’Aringa, Vitalina Komashko, Nurgul Kilavuz, Richard Delarue, Myron Czuczman, Lars Sternas, Shelonitda Rose, C. L. Beach, Steven Novick, Simon Zhou, Maria Palmisano, Yan Li
Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects
Carlos Pérez-Ruixo, Jonás Samuel Pérez-Blanco, Caly Chien, Margaret Yu, Daniele Ouellet, Juan-José Pérez-Ruixo, Oliver Ackaert
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup
Pierre Chelle, Cindy H. T. Yeung, Stacy E. Croteau, Jennifer Lissick, Vinod Balasa, Christina Ashburner, Young Shil Park, Santiago Bonanad, Juan Eduardo Megías-Vericat, Azusa Nagao, Tung Wynn, Fernando Corrales-Medina, Huyen Tran, Anjali Sharathkumar, Meera Chitlur, Samuel Sarmiento, Andrea Edginton, Alfonso Iorio
Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus
Nienke J. Vet, Brenda C. M. de Winter, Muriel Koninckx, Shelley A. Boeschoten, Annemie L. M. Boehmer, Jacintha T. Verhallen, Frans B. Plötz, Anja A. Vaessen-Verberne, Bart C. H. van der Nagel, Catherijne A. J. Knibbe, Corinne M. P. Buysse, Saskia N. de Wildt, Birgit C. P. Koch, Matthijs de Hoog
Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
Axel Krebs-Brown, Alain Munafo, Sumedh Gaikwad, Bogumila Urgatz, Claire Castello-Bridoux
Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
D. Concordet, P. Gandia, J. L. Montastruc, A. Bousquet-Mélou, P. Lees, A. A. Ferran, P. L. Toutain
Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, Pierre-Louis Toutain
Comment on “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
Yang Yu, Marc Maliepaard
Authors’ Reply to Yu et al.: “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?”
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, Pierre-Louis Toutain